New hope for leukemia patients as experimental drug enters first human tests
NCT ID NCT07429461
Summary
This is a very early study to check if a new drug called SYNCAR-100 is safe and shows any promise for adults with a specific type of leukemia that has come back or hasn't responded to other treatments. Up to 16 participants will receive four weekly doses of the drug, followed by a year of close monitoring for safety and any signs the leukemia is responding. The study will also track participants' health for up to 15 years after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of medical college of zhejiang university
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.